Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-08-25
Target enrollment:
Participant gender:
Summary
This dose escalation and dose expansion study is to evaluate and characterize the
tolerability and safety profile of single agent KN035 in Chinese adult subjects with
unresectable advanced carcinoma.